Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Khosla Ventures
BioCentury | Feb 28, 2025
Product Development
Intellia: Balancing in vivo risk with validated targets
Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | Sep 12, 2024
Management Tracks
Ovid promotes Alexander to COO
Plus: Tyra hires Warner as CMO and updates from Senisca, Closed Loop, NanoSyrinx and more
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Sep 5, 2024
Finance
Venture Report: Megarounds for ArsenalBio, eGenesis
Developers of programmable CAR T therapies and human-compatible organs for transplantation garner nine-figure fundings
BioCentury | Aug 30, 2024
Finance
Finance Report: RA, Forbion back immunology play Navigator to develop bispecific
Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
BioCentury | Jul 5, 2024
Product Development
LNP innovation: tissue specificity, aided by AI
How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Apr 10, 2024
Emerging Company Profile
Moonwalk: Mapping the methylome to create epigenome editors
With CRISPR pioneer Feng Zhang among its founders, Moonwalk aims to control gene expression via epigenetic editing
Items per page:
1 - 10 of 105